VK-0214
VK-0214
VK-0214 is a novel, orally bioavailable small molecule that acts as a selective thyroid hormone receptor beta (TRβ) agonist. It is currently under investigation for its potential therapeutic effects in treating X-linked adrenoleukodystrophy (X-ALD), a rare genetic disorder affecting the nervous system and adrenal glands.
Mechanism of Action[edit | edit source]
VK-0214 selectively targets the thyroid hormone receptor beta (TRβ), which is predominantly expressed in the liver and central nervous system. By activating TRβ, VK-0214 is believed to modulate the expression of genes involved in lipid metabolism, potentially reducing the accumulation of very long-chain fatty acids (VLCFAs) that are characteristic of X-ALD.
Clinical Development[edit | edit source]
VK-0214 is currently in the clinical trial phase, with studies focusing on its safety, tolerability, and efficacy in patients with X-ALD. Preclinical studies have shown promising results, indicating that VK-0214 can reduce VLCFA levels and improve neurological outcomes in animal models.
Potential Benefits[edit | edit source]
The selective activation of TRβ by VK-0214 offers a targeted approach to managing X-ALD, potentially minimizing the side effects associated with non-selective thyroid hormone therapies. By reducing VLCFA accumulation, VK-0214 may help slow the progression of neurological symptoms and improve quality of life for patients with X-ALD.
Side Effects and Safety[edit | edit source]
As with any investigational drug, the safety profile of VK-0214 is being closely monitored in clinical trials. Common side effects observed in early studies include mild gastrointestinal disturbances and transient increases in liver enzymes. Long-term safety data are still being collected.
Research and Future Directions[edit | edit source]
Ongoing research aims to further elucidate the molecular mechanisms by which VK-0214 exerts its effects and to optimize its therapeutic potential. Future studies may explore its use in other disorders characterized by lipid metabolism abnormalities.
Also see[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
